Clinical trial NCT05429762: Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors
Official title: Open-label Study Evaluating the Effect of Tusamitamab Ravtansine on the QTc Interval in Participants With Metastatic Solid Tumors
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Neoplasm
Lead sponsor: Sanofi
Sponsor class: INDUSTRY
First posted: 2022-06-23
Enrollment: 56
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is a Phase1, single-arm study for treatment. This is a prospective multicenter, multinational, open-label study to assess the effect of tusamitamab ravtansine on the QT interval in participants with metastatic colorectal cancer (CRC), nonsquamous non small cell lung cancer (NSQ NSCLC), or gastric/ gastroesophageal junction (GEJ) adenocarcinoma for which in the judgement of the Investigator, no standard alternative therapy is available.

Detailed description: This is a single arm study in which participants will receive treatment with tusamitamab ravtansine until disease progression, unacceptable toxicity, the start of a new anti-cancer therapy, or the participant's or Investigator's decision to stop the treatment, whichever comes first.

Eligibility criteria: Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of colorectal cancer (CRC) adenocarcinoma, nonsquamous non small cell lung cancer (NSQ NSCLC), or gastric/ gastroesophageal junction (GC/GEJ) adenocarcinoma, metastatic disease at study entry.
* Participants with documented disease progression, for which, in the judgment of the Investigator, no alternative medical therapy is available.
* Expression of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) will be assessed centrally using the most recent archival tumor tissue (or, if not available, a fresh biopsy sample) and at least 5 fresh-cut slides of formalin-fixed paraffin embedded (FFPE) tumor tissue sectioned. If less material is available, the participant could still be considered eligible after discussion with the Sponsor.

  * Participants with CRC tumors may be assumed to have adequate CEACAM5 expression without testing results (it will be assessed retrospectively),
  * Participants with NSQ NSCLC must have tumors expressing CEACAM5 or high circulating CEA if tumor tissue is not available.
  * Participants with GC/GEJ must have tumors expressing CEACAM5
* Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, as determined by the Investigator.
* Eastern Cooperative Oncology Group (ECOG) performance status 0 to1.
* A female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP) and is a WOCBP and agrees to use a contraceptive method that is highly effective and for at least 7 months after the last dose of treatment. administration.
* Male participant who agrees to use effective contraception methods during and for at least 4 months after the last dose of treatment administration.
* Capable of giving signed informed consent.

Exclusion Criteria:

* Untreated brain metastases that may be considered active or leptomeningeal metastasis. A participant with asymptomatic brain metastasis/metastases is eligible.
* Significant concomitant illness
* History within the last 2 years of an invasive malignancy other than that treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment.
* Any major surgery within 3 weeks prior to of first study intervention administration.
* Known uncontrolled infection with human immunodeficiency virus (HIV). Participants with a well-controlled HIV infection/disease must be on antiretroviral therapy (ART) to be eligible.
* Active infection with hepatitis A, B, or C.
* Nonresolution of any prior treatment-related toxicity .
* Unresolved corneal disorder or any previous corneal disorder.
* Use of contact lenses is not permitted.
* Prior history of Torsades de Pointes, or congenital long QT syndrome.
* Patient receives (and cannot discontinue) or is scheduled to receive a QT-prolonging drug unless if deemed necessary for the participant as per the investigators' judgment and started at least 4 weeks prior IMP administration at the same dose and the same frequency.
* QTcF interval \>480 msec on screening ECG.
* Poor bone marrow, liver, kidney functions, or electrolytes values
* Participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.

Primary outcomes:
measure: Change from baseline in QT-interval corrected (QTcF) centrally assessed
timeFrame: Baseline, Cycle 1, and Cycle 2 (1 Cycle = 2 weeks)
Secondary outcomes:
measure: Electrocardiogram (ECG) parameter: heart rate (HR)
timeFrame: Baseline, Cycle 1, and Cycle 2 (1 Cycle = 2 weeks)
measure: ECG parameter: QT interval
timeFrame: Baseline, Cycle 1, and Cycle 2 (1 Cycle = 2 weeks)
measure: ECG parameter: QT interval corrected according to the Bazett's formula (QTcB)
timeFrame: Baseline, Cycle 1, and Cycle 2 (1 Cycle = 2 weeks)
measure: ECG parameter: QRS interval
timeFrame: Baseline, Cycle 1, and Cycle 2 (1 Cycle = 2 weeks)
measure: ECG parameter: PR interval
timeFrame: Baseline, Cycle 1, and Cycle 2 (1 Cycle = 2 weeks)
measure: Maximum concentration observed (Cmax)
timeFrame: Multiple timepoint at Cycle 1 (1 Cycle = 2 weeks)
measure: Area under the plasma concentration versus time curve from time 0 to 14 days (AUC0-14d)
timeFrame: Multiple timepoint at Cycle 1 (1 Cycle = 2 weeks)
measure: Incidence of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and laboratory abnormalities
timeFrame: From the date of first infusion up to approximately 30 days after the last infusion i.e., up approximately 34 weeks
measure: Overall response rate (ORR)
timeFrame: Up to approximately 30 weeks
measure: Duration of response (DOR)
timeFrame: Up to approximately 30 weeks
Other outcomes:
Locations:
city: Dallas
country: United States
facility: Mary Crowley Cancer Research Center Site Number : 8400002
state: Texas
city: Edegem
country: Belgium
facility: Investigational Site Number : 0560001
city: Dijon
country: France
facility: Investigational Site Number : 2500001
city: Marseille
country: France
facility: Investigational Site Number : 2500002
city: Barcelona
country: Spain
facility: Investigational Site Number : 7240002
state: Catalunya [Cataluña]
city: Madrid
country: Spain
facility: Investigational Site Number : 7240001
state: Madrid, Comunidad De
city: Ankara
country: Turkey
facility: Investigational Site Number : 7920001
Study officials:
affiliation: Sanofi
name: Clinical Sciences & Operations
role: STUDY_DIRECTOR
References: